C3i is attending the World Stem Cell Summit 2018 in Miami next week!
C3i will attend both the Cell and Gene Therapy World and Immuno-Oncology Frontiers World (part of the World Stem Cell Summit 2018) in Miami to engage with researchers, clinicians and industry leaders in the Stem Cell field. Arnaud Deladeriere, representative of the cGMP Manufacturing unit at the summit, will be promoting C3i for its outstanding capacity to help biotech companies and pharmas to achieve their GMP manufacturing objectives.
C3i was on the ground at ISSCR 2026 in Montréal, where one message came through clearly: cell and gene therapy is moving from scientific promise to clinical and commercial reality. Academia and industry have taken meaningful steps forward this past year, and the momentum is building. A few takeaways stood out: Clinical progress is accelerating […]
The C3i team recently wrapped up a busy week at the BIO International Convention in San Diego, where renewed investment, artificial intelligence, and cross-border collaboration set the tone for biotech in the year ahead. Three themes stood out on the show floor: A rebounding market. Investment is picking up across the biotech ecosystem, and with […]
For the first time in Canada, blood stem cells were genetically modified using CRISPR-Cas9 technology and subsequently injected into patients as part of a North American clinical trial targeting acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Every graft used in this landmark study was produced in Montreal, at Hôpital Maisonneuve-Rosemont, through the biomanufacturing expertise […]
